Literature DB >> 33239427

Hyal2 Expression in Tumor-Associated Myeloid Cells Mediates Cancer-Related Inflammation in Bladder Cancer.

Paul R Dominguez-Gutierrez1, Elizabeth P Kwenda1, William Donelan1, Padraic O'Malley1, Paul L Crispen1, Sergei Kusmartsev2.   

Abstract

The increased presence of myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) in tumor tissue has been extensively reported. However, their role in the regulation of hyaluronan (HA) metabolism in the tumor microenvironment has not been established. Here we describe a novel function of tumor-associated myeloid cells related to the enhanced breakdown of extracellular HA in human bladder cancer tissue, leading to the accumulation of small HA fragments with molecular weight (MW) <20 kDa. Increased fragmentation of extracellular HA and accumulation of low molecular weight HA (LMW-HA) in tumor tissue was associated with elevated production of multiple inflammatory cytokines, chemokines, and angiogenic factors. The fragmentation of HA by myeloid cells was mediated by the membrane-bound enzyme hyaluronidase 2 (Hyal2). Increased numbers of Hyal2+CD11b+ myeloid cells were detected in the tumor tissue as well as in the peripheral blood of patients with bladder cancer. Coexpression of CD33 suggested that these cells belong to monocytic myeloid-derived suppressor cells. The HA-degrading function of Hyal2-expressing MDSCs could be enhanced by exposure to tumor-conditioned medium, and IL1β was identified as one of the factors involved in the stimulation of Hyal2 activity. CD44-mediated signaling played an important role in the regulation of HA-degrading activity of Hyal2-expressing myeloid cells, as the engagement of CD44 receptor with specific mAb triggered translocation of Hyal2 enzyme to the cellular surface and stimulated secretion of IL1β. Taken together, this work identifies Hyal2-expressing tumor-associated myeloid cells as key players in the accumulation of LMW-HA in the tumor microenvironment and cancer-related inflammation and angiogenesis. SIGNIFICANCE: This study identifies Hyal2-expressing tumor-associated myeloid cells of monocyte-macrophage lineage as contributors to hyaluronan degradation in bladder cancer tissue, leading to accumulation of inflammatory and proangiogenic low molecular weight hyaluronan fragments. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33239427     DOI: 10.1158/0008-5472.CAN-20-1144

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease.

Authors:  Zhijia Zhou; Penghua Lai; Shaoliang Zhang; Yujie Wang; Ning Qu; Dawei Lu; Liangqin Gao; Lingxia Xu; Yanmiao Yang; Ting Zhang; Xue Sun; Xiaoting Zheng; Yaoyu Liu; Huiqing Liang; Shaodong Chen
Journal:  Biomed Res Int       Date:  2021-03-29       Impact factor: 3.411

Review 2.  The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.

Authors:  Piia Takabe; Hanna Siiskonen; Aino Rönkä; Kirsi Kainulainen; Sanna Pasonen-Seppänen
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

3.  High Levels of PD-L1+ and Hyal2+ Myeloid-derived Suppressor Cells in Renal Cell Carcinoma.

Authors:  Sergei Kusmartsev; Elizabeth Kwenda; Paul R Dominguez-Gutierrez; Paul L Crispen; Padraic O'Malley
Journal:  J Kidney Cancer VHL       Date:  2022-04-16

4.  Is periodontal disease a risk indicator for urogenital cancer? A systematic review and meta-analysis of cohort studies.

Authors:  Weiqi Li; Simin Wang; Yuhan He; Yongshang Zhang; Shanfeng Lin; Dongdong Cen; Li Lin
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

Review 5.  Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression.

Authors:  William Donelan; Paul R Dominguez-Gutierrez; Sergei Kusmartsev
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.